Carcinoma of pharynx

Summary

Carcinoma of pharynx (MONDO:0021345) is a cancer (an umbrella term covering 6 Mondo subtypes) and 5 clinical trials. Top therapeutic interventions include docetaxel anhydrous, hydroxyurea, and cisplatin. A subtype of digestive system carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 6 Mondo subtypes
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinoma of pharynx
Mondo ID	MONDO:0021345
NCIT	C9466
SNOMED CT	449254004
UMLS	C3164746
MedGen	757152
Anatomy (UBERON)	UBERON:0006562
Is cancer (heuristic)	yes

Also known as: cancer of the pharynx · carcinoma of pharynx · carcinoma of the pharynx · pharyngeal carcinoma · pharyngeal throat cancer · pharynx carcinoma

Disease family

This is a subtype of digestive system carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › digestive system carcinoma › carcinoma of pharynx

Related subtypes (15): maxillary sinus carcinoma, gastroesophageal junction adenocarcinoma, gallbladder carcinoma, intestine carcinoma in situ, gastric carcinoma, exocrine pancreatic carcinoma, small intestine carcinoma, pancreatic endocrine carcinoma, ameloblastic carcinoma, digestive system mixed adenoneuroendocrine carcinoma, carcinoma of liver and intrahepatic biliary tract, carcinoma of esophagus, carcinoma of floor of mouth, colorectal carcinoma, oral cavity carcinoma

Subtypes (6): pharynx carcinoma in situ, pharyngeal squamous cell carcinoma, hypopharyngeal carcinoma, pharyngeal adenoid cystic carcinoma, nasopharyngeal carcinoma, oropharyngeal carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00117572	PHASE3	COMPLETED	Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
NCT00462735	PHASE2	COMPLETED	Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
NCT00970502	PHASE1/PHASE2	COMPLETED	Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
NCT01552434	PHASE1	TERMINATED	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
NCT05992610	Not specified	UNKNOWN	Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOCETAXEL ANHYDROUS	4	3
HYDROXYUREA	4	2
CISPLATIN	4	1
CHEMBL1510899	0	1